Aspira Women`s Health Inc Stock Price, News & Analysis

Aspira Women’s Health, Inc. (AWH) will release its financial results for Q1 2022 on May 11, 2022, prior to market opening. A conference call is scheduled for 8:30 AM ET to discuss these results and provide a corporate update. Aspira focuses on innovative testing solutions for women’s health, striving to improve gynecologic outcomes, particularly in ovarian cancer risk assessment. The company has launched Aspira Synergy technology to enhance testing accessibility and is developing new diagnostic products.

Aspira Women's Health (AWH) reported a 46% increase in total revenue for 2021, reaching $6.8 million, driven by a 28% growth in OVA1plus test volume to 17,359 units. The company exercised a world-wide license option for cutting-edge miRNA technology in collaboration with Harvard Dana-Farber Cancer Institute. Despite a 153% rise in research and development expenses and a 60% increase in general and administrative costs, the gross profit margin for OVA1plus improved to 55%. Aspira ended the year with $37.42 million in cash and is optimistic about future growth.

Aspira Women’s Health (AWH) will report its financial results for the year ended December 31, 2021, on March 23, 2022, prior to market opening. A conference call with investors is scheduled for 8:30 AM ET on the same day to discuss the results and provide corporate updates. Aspira specializes in innovative women's health solutions, particularly focusing on ovarian cancer risk assessment and pelvic diseases. With over a decade of expertise, they are advancing their portfolio with new products like OVAWatch and EndoCheck, aiming to enhance gynecologic health outcomes.

Aspira Women’s Health (AWH) appointed Celeste Fralick, Ph.D., to its Board of Directors effective February 23, 2022. Dr. Fralick brings over 40 years of data strategy experience, particularly in healthcare and technology. Notable for her leadership roles at McAfee and Intel, she has been recognized by Forbes as one of the Top 50 Women in Technology. The Board's Chair, James LaFrance, and President, Valerie Palmieri, expressed confidence in her capabilities to guide the company’s expanding portfolio and initiatives aimed at enhancing women's health outcomes.

Aspira Women’s Health Inc. (Nasdaq: AWH) announced changes in its leadership team effective March 1, 2022. Valerie Palmieri transitions to Executive Chair of the Board, while Nicole Sandford takes on the role of President and CEO. Jim LaFrance will become Lead Independent Director. Palmieri's tenure as CEO has been marked by significant advancements in women's health diagnostics, particularly in ovarian cancer. Sandford, joining from the Ellig Group, aims to leverage her extensive operational experience to boost product launches and drive growth.

Aspira Women’s Health (Nasdaq: AWH) has appointed Mr. Michael Newton as the new Head of Sales and Marketing, bringing over 20 years of experience in diagnostics to the company. Newton will oversee U.S. commercialization, focusing on driving adoption of the OVA1Plus product for early ovarian cancer risk detection. President and CEO Valerie Palmieri expressed enthusiasm for Newton's strategic expertise in enhancing product adoption and market growth. Aspira aims to solidify its position in gynecologic health with innovative testing solutions and advanced technology transfer.

Aspira Women’s Health (Nasdaq: AWH) announced its participation in the 2nd Annual Winter Wonderland Best Ideas Conference from February 8-11, 2022. Management will present on February 9 at 9:00 AM ET, accessible via a webcast. Additionally, one-on-one virtual meetings will be held on February 10-11. Aspira focuses on women's health through innovative testing and bio-analytical solutions, particularly in ovarian cancer risk assessment. Their products include OVA1plus™ and Aspira GenetiX™.

Aspira Women’s Health, Inc. (Nasdaq: AWH) announced agreements to provide testing services to nearly 500,000 Medicaid members in New Hampshire and Washington, D.C. This expansion brings Aspira's OVA1 testing to around 80% of the U.S. Medicaid population, totaling about 60 million lives. CEO Valerie Palmieri emphasized the company's commitment to ensuring equal access to non-invasive ovarian cancer risk assessments. Aspira aims for full credentialing of Medicaid lives across the U.S., enhancing their testing solutions and addressing ethnic disparities in ovarian cancer.

Aspira Women’s Health Inc. (Nasdaq: AWH) has partnered with Axia Women’s Health, a leading women’s health network, to enhance genetic testing services for nearly half a million patients annually. The five-year agreement allows Axia providers to conduct in-house genetic testing using the Aspira Synergy Genetics platform, providing customized carrier screening and hereditary cancer risk assessments.

This collaboration aims to improve patient care through early risk detection and personalized health management solutions, leveraging advanced technology and AI-driven bioinformatics.